Merck announced the U.S. FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev, an antibody-drug conjugate, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. The FDA approved this application nearly five months ahead of the PDUFA goal date of May 9, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRK:
- Leerink skeptical on sustainability of Moderna rally given eroding fundamentals
- Moderna’s (NASDAQ:MRNA) Positive Melanoma Trial Data Sparks Stock Surge
- Moderna, Merck announc e follow-up data on V940 with Keytruda
- Goldman Sachs Says These 3 Healthcare Giants Look Very Attractive Right Now
- Merck price target lowered by $2 at Morgan Stanley, here’s why